Anticonvulsant medication use for the management of pain following spinal cord injury: Systematic review and effectiveness analysis

Aging, Rehabilitation and Geriatric Care, Lawson Health Research Institute, London, ON, Canada.
Spinal Cord (Impact Factor: 1.8). 12/2013; 52(2). DOI: 10.1038/sc.2013.146
Source: PubMed


Study design:Systematic review and effectiveness analysis.Objectives:Assess the effectiveness of anticonvulsants for the management of post spinal cord injury (SCI) neuropathic pain.Setting:Studies from multiple countries were included.Methods:CINAHL, Cochrane, EMBASE and MEDLINE were searched up to April 2013. Quality assessment was conducted using the Jadad and the Downs and Black tools. Effect sizes and odds ratios were calculated for primary and secondary outcome in the included studies.Results:Gabapentinoids, valproate, lamotrigine, levetiracetam and carbamazepine were examined in the 13 included studies, ten of which are randomized controlled trials. Large effect size (0.873-3.362) for improvement of pain relief was found in 4 of the 6 studies examining the effectiveness of gabapentin. Pregabalin was shown to have a moderate to large effect (0.695-3.805) on improving neuropathic pain post SCI in 3 studies. Valproate and levetiracetam were not effective in improving neuropathic pain post SCI, while lamotrigine was effective in reducing neuropathic pain amongst persons with incomplete lesions and carbamazepine was found effective for relief of moderate to intense pain.Conclusion:Gabapentin and pregabalin are the two anticonvulsants which have been shown to have some benefit in reducing neuropathic pain.Spinal Cord advance online publication, 3 December 2013; doi:10.1038/sc.2013.146.

Download full-text


Available from: Swati Mehta, Jul 09, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic pain is a substantial and serious problem that many people with spinal cordinjury (SCI) live with, and it has the potential to significantly impair their function andquality of life. Approximately 65% of people are affected by pain after SCI, with aroundone third of these experiencing severe pain. The most common classification schemeused for this group of pain disorders divides them into two broad types: nociceptive andneuropathic pain. While the mechanisms underlying the former are reasonably wellunderstood and thought to be similar to those observed in other pain populations,neuropathic pain conditions are less well explained. Biopsychosocial models of pain inSCI are receiving increasing attention. Biological changes in spinal cord and brainanatomy, neurochemical and excitotoxic changes, inflammatory changes and sympatheticinvolvement are all thought to play a role in the development of pain. Importantpsychological factors include cognitions and affect. Social factors are perhaps leastexplored but their significance is increasingly being highlighted. Pain in SCI, particularlyneuropathic pain, is often refractory to current treatments, such as medication andsurgery. Recent exploration of the application of cognitive behavioural pain managementprogrammes, and novel applications of treatments for other neuropathic pain conditions,such as complex regional pain syndrome, offer hope for the future both in amelioratingthe effects of pain on quality of life and ultimately pain relief.
    No preview · Article · Apr 2008
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Study design:Review article.Objectives:To review the literature regarding treatment approaches in cases of gunshot wounds (GSWs) affecting the spine.Setting:Brazil.Methods:Narrative review of medical literature.Results:GSWs are an increasing cause of morbidity and mortality. Most patients with spinal GSW have complete neurological deficit. The injury is more common in young men and is frequently immobilizing. The initial approach should follow advanced trauma life support, and broad-spectrum antibiotic therapy should be initiated immediately, especially in patients with perforation of the gastrointestinal tract. The indications for surgery in spinal GSW are deterioration of the neurologic condition in a patient with incomplete neurological deficit, the presence of liquor fistula, spinal instability, intoxication by the metal from the bullet or risk of bullet migration.Conclusion:Surgical treatment is associated with a higher complication rate than conservative treatment. Therefore, the surgeon must know the treatment limitations and recognize patients who would truly benefit from surgery.Spinal Cord advance online publication, 29 April 2014; doi:10.1038/sc.2014.56.
    Full-text · Article · Apr 2014 · Spinal Cord
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the efficacy of venlafaxine XR for the treatment of pain (secondary aim) in individuals with spinal cord injury (SCI) enrolled in an RCT on the efficacy of venlafaxine XR for major depressive disorder (MDD: primary aim). It was hypothesized that venlafaxine XR would be effective for both neuropathic and nociceptive pain. Multi-site, double-blind, randomized (1:1) controlled trial with subjects block randomized and stratified by site, lifetime history of substance abuse and prior history of MDD. Six Departments of Physical Medicine and Rehabilitation in University based medical schools. 123 individuals with SCI and major depression between 18 and 64, at least 1 month post-SCI who also reported pain. Twelve-week trial of venlafaxine XR versus placebo using a flexible titration schedule. 0-10 numerical rating scale for pain, pain interference items of the Brief Pain Inventory; 30% and 50% responders. The effect of venlafaxine XR on neuropathic pain was similar to placebo. However venlafaxine XR resulted in statistically significant and clinically meaningful reductions in nociceptive pain site intensity and interference even after controlling for anxiety, depression and multiple pain sites within the same individual. For those who achieved a minimally effective dose of venlafaxine XR, some additional evidence of effectiveness was noted for those with mixed (both neuropathic and nociceptive) pain sites. Venlafaxine XR could complement current medications and procedures for treating pain after SCI and MDD which has nociceptive features. Its usefulness for treating central neuropathic pain is likely to be limited. Research is needed to replicate these findings and determine whether the antinociceptive effect of venlafaxine XR generalizes to persons with SCI pain without MDD. Copyright © 2014 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.
    No preview · Article · Dec 2014 · Archives of Physical Medicine and Rehabilitation
Show more